Apolipoprotein E (apoE) polymorphism is associated with onset of Alzheimer's disease (AD). We found seven polymorphisms in apoE receptor 2 (ApoER2), an apoEbinding receptor, in Japanese sporadic AD patients, but no association of ApoER2 polymorphisms with AD. We consider that the functions of ApoER2 in the brain may be compensated for by those of other apoE-binding receptors such as VLDL receptor.
Alzheimer's disease (AD) is a progressive neurodegenerative disease of the central nervous system (CNS). The "4 allele of apolipoprotein E (apoE), APOE"4, has been found to be a genetic susceptibility risk factor in both sporadic and late-onset familial AD. 1, 2) Although the major site of apoE synthesis is the liver, significantly high levels of apoE are synthesized in the brain and secreted by astrocytes.
3) ApoE synthesis is dramatically increased after injury to the rat sciatic or optic nerve. 4) The apoE-containing lipoproteins secreted by astrocytes appear to be transported into other cells in the brain via receptor-mediated endocytosis. Hence, the receptors for apoE-containing lipoproteins have been proposed to be associated with the onset of AD.
5)
Sakai et al. 6) have found that the very low density lipoprotein receptor (VLDLR) binds only apo-E containing lipoproteins with high affinity. Like the low density lipoprotein receptor (LDLR), the VLDLR consists of five functional domains: (i) a ligand binding domain composed of multiple cysteine-rich repeats; (ii) an epidermal growth factor (EGF) precursor homology domain together with a Tyr-Trp-Thr-Asp (YWTD) amino acid repeat that together form a -propeller structure; (iii) an O-linked sugar domain; (iv) a transmembrane domain; and (v) a cytoplasmic domain with a coated pit targeting signal. The human VLDLR contains 19 exons spanning 40 kb located on chromosome 9p24. The VLDLR is highly expressed in the brain as well as the heart, muscle, and adipose tissue. Okuizumi et al. 7) performed an association study using a polymorphic triplet (CGG) repeat in the 5 0 -untranslated region (5 0 -UTR) of the VLDLR. They found a significant association of the VLDLR gene with sporadic AD: the frequency of the 5-repeat allele was significantly higher in the Japanese sporadic AD patients than in Japanese controls.
We have isolated an apoE receptor 2 (ApoER2) that binds apoE-containing lipoproteins with high affinity. 8) The ApoER2 consists of five functional domains characteristic of the LDLR family. The human gene for ApoER2 consists of 19 exons within 60 kb on chromosome 1p34, and its genomic organization closely resembles that of the LDLR and VLDLR genes. 9) ApoER2 is predominantly expressed in the brain, and it plays a significant role in development of the central nervous system (CNS) in collaboration with VLDLR. ApoER2 and VLDLR also bind Reelin, an extracellular glycoprotein that plays a crucial role in the architectonic development of the CNS. 10) Binding of Reelin to ApoER2 and VLDLR induces tyrosine phosphorylation of the adaptor protein Disabled-1 (Dab1), which binds to the cytoplasmic tails of both receptors. A lack of Reelin, of both ApoER2 and VLDLR, or of Dab1 results in the same neuroanatomic abnormalities: cerebellar dysplasia and scrambling of the neuronal layers in the neocortex. 11) We predicted that the ApoER2 gene is a susceptibility gene for AD. Hence, in the present study, we analyzed polymorphisms in the ApoER2 genes of Japanese sporadic AD patients and normal subjects.
In this study, genomic DNA samples from Japanese sporadic AD patients (n ¼ 118) and normal subjects (n ¼ 104) were obtained as described previously.
12) The study was approved by the Research Ethics Committee of the Graduate School of Human Life Science of Osaka City University.
All 19 exons and relevant exon-intron boundaries of the human ApoER2 genes were amplified by polymerase chain reaction (PCR) and directly sequenced. Primers for PCR and sequencing analysis were designed based on the human DNA sequence from clones RP4-784A16 and RP5-1024G6 on the chromosome 1 complete sequence (GenBank accession nos. AL355483 and AL606760 respectively). The volume of the final reaction mixture was 50 ml, containing 20-50 ng of genomic DNA, 0.5 mM each set of forward and reverse primers (Table 1) , 1 unit y To whom correspondence should be addressed. Tel: +81-6-6605-2869; Fax: +81-6-6605-2817; E-mail: saeki@life.osaka-cu.ac.jp of Ex Taq polymerase (Takara, Kyoto, Japan), and PCR buffer. The reaction mixture was heated to 94 C for 3 min, followed by 33 cycles of annealing for 60 s at the indicated temperatures (Table 1) , and finally elongation at 72 C for 90 s. For amplification of the 5 0 -UTR and exons 1-3, dimethyl sulfoxide (final concentration, 10%) was added to avoid non-specific amplification. The PCR products were separated by electrophoresis on 2% agarose gels, purified, and directly sequenced using an ABI PRISM 373A genetic analyzer (Applied Biosystems, Foster City, CA). The coding sequence of human ApoER2 was compared with GenBank accession no. NM 004631. Amino acids were numbered according to GenBank accession no. NP 004622. Sequence variants were verified by restriction enzyme fragment polymorphism analysis.
Direct sequencing of the human ApoER2 genes in AD patients and normal subjects revealed seven novel sequence variants. We found polymorphisms in the length of the CGG repeat (6-, 7-, and 8-fold repeated alleles) located at 5 0 -UTR of the human ApoER2 gene ( Table 2) . We also found polymorphisms in the length of a CTG repeat (10-and 11-fold repeated alleles) in the signal sequence encoded by exon 1 ( Table 2 ). This triplet repeat encodes a polyleucine stretch in the signal sequence of human ApoER2. There was no genetic association between the two triplet repeats and AD.
We also found two variants in the ligand-binding domain that replaced amino acids at positions 46 and 299: c.374G > T: E46D in exon 2 and c.1132G > A: C299Y in exon 6 (Table 3 ). There were three other variants in the coding region that did not replace amino acids, 977C > T: R247R in exon 5, 1346C > T: D370D in exon 7, and c.3018G > T: P927P in exon 18. The allelic frequencies of the E46D variant were 52% and 53% in the AD patients and normal subjects respectively. There was one C299Y allele in the AD patients and two in the normal subjects. These data suggest that amino acid substitutions at residue 46 and 299 are not associated with AD. No disease-causing mutations, such as nonsense, splicing, or deletion/insertion, were found in the AD patients (Table 3 ).
An increase in phosphorylation of the microtubulestabilizing protein tau is induced in mice lacking ApoER2 and VLDLR.
10) Both ApoER2 and VLDLR play a role in hippocampal synaptic plasticity and learning. 11) Although these studies suggest the involvement of ApoER2 and VLDLR in AD onset, the present study suggests a lack of genetic association between the ApoER2 gene and AD. ApoER2 and VLDLR bind the same ligand, and mice lacking a single receptor exhibit only a minor phenotype in the brain. 11) Hence, we consider that ApoER2 and VLDLR might compensate for each other's function in the brain when either of them is disordered. Further studies are necessary to determine the polymorphisms in the VLDLR genes of Japanese sporadic AD patients and normal subjects, and to compare the frequency of AD induced by polymorphisms in either the ApoER2 or the VLDLR gene with that induced by polymorphisms in both genes.
